Cephalon Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CEPHALON
CEPHALON has six approved drugs.
There are eleven US patents protecting CEPHALON drugs.
Summary for Cephalon
| US Patents: | 11 |
| Tradenames: | 6 |
| Ingredients: | 4 |
| NDAs: | 6 |
| Patent Litigation for Cephalon: | See patent lawsuits for Cephalon |
| PTAB Cases with Cephalon as patent owner: | See PTAB cases with Cephalon as patent owner |
Drugs and US Patents for Cephalon
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cephalon | GABITRIL | tiagabine hydrochloride | TABLET;ORAL | 020646-005 | Apr 16, 1999 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Cephalon | TREANDA | bendamustine hydrochloride | POWDER;INTRAVENOUS | 022249-002 | May 1, 2009 | AP | RX | Yes | Yes | 9,533,955*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Cephalon | FENTORA | fentanyl citrate | TABLET;BUCCAL, SUBLINGUAL | 021947-003 | Sep 25, 2006 | DISCN | Yes | No | 7,862,833 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Cephalon | GABITRIL | tiagabine hydrochloride | TABLET;ORAL | 020646-004 | Sep 30, 1997 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Cephalon | FENTORA | fentanyl citrate | TABLET;BUCCAL, SUBLINGUAL | 021947-004 | Sep 25, 2006 | DISCN | Yes | No | 7,862,832 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Cephalon | FENTORA | fentanyl citrate | TABLET;BUCCAL, SUBLINGUAL | 021947-005 | Sep 25, 2006 | DISCN | Yes | No | 7,862,832 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Cephalon
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cephalon | ACTIQ | fentanyl citrate | TROCHE/LOZENGE;TRANSMUCOSAL | 020747-003 | Nov 4, 1998 | 4,671,953 | ⤷ Start Trial |
| Cephalon | FENTORA | fentanyl citrate | TABLET;BUCCAL, SUBLINGUAL | 021947-004 | Sep 25, 2006 | 8,765,100 | ⤷ Start Trial |
| Cephalon | ACTIQ | fentanyl citrate | TROCHE/LOZENGE;TRANSMUCOSAL | 020747-002 | Nov 4, 1998 | 5,785,989 | ⤷ Start Trial |
| Cephalon | ACTIQ | fentanyl citrate | TROCHE/LOZENGE;TRANSMUCOSAL | 020747-002 | Nov 4, 1998 | 4,863,737 | ⤷ Start Trial |
| Cephalon | ACTIQ | fentanyl citrate | TROCHE/LOZENGE;TRANSMUCOSAL | 020747-002 | Nov 4, 1998 | 4,671,953 | ⤷ Start Trial |
| Cephalon | ACTIQ | fentanyl citrate | TROCHE/LOZENGE;TRANSMUCOSAL | 020747-005 | Nov 4, 1998 | 4,863,737 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CEPHALON drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Lozenges | 0.4 mg | ➤ Subscribe | 2004-10-06 |
| ➤ Subscribe | Lozenges | 0.8 mg, 1.2 mg and 1.6 mg | ➤ Subscribe | 2004-11-22 |
| ➤ Subscribe | Injection | 1 mg/mL | ➤ Subscribe | 2015-08-11 |
| ➤ Subscribe | Injection | 90 mg/mL, 0.5 mL and 2 mL in single-dose vials | ➤ Subscribe | 2014-06-19 |
| ➤ Subscribe | Tablets | 2 mg and 4 mg | ➤ Subscribe | 2005-02-01 |
| ➤ Subscribe | Lozenges | 0.2 mg | ➤ Subscribe | 2004-10-29 |
| ➤ Subscribe | Lozenges | 0.6 mg | ➤ Subscribe | 2004-12-20 |
| ➤ Subscribe | Injection | 25 mg/vial and 100 mg/vial | ➤ Subscribe | 2013-06-04 |
| ➤ Subscribe | Buccal Tablets | 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.6 mg and 0.8 mg | ➤ Subscribe | 2007-11-13 |
| ➤ Subscribe | Tablets | 12 mg and 16 mg | ➤ Subscribe | 2014-01-24 |
International Patents for Cephalon Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Ukraine | 91824 | ⤷ Start Trial |
| China | 101119708 | ⤷ Start Trial |
| Taiwan | I380830 | ⤷ Start Trial |
| European Patent Office | 2889029 | ⤷ Start Trial |
| Mexico | 339878 | ⤷ Start Trial |
| Japan | 2012503666 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cephalon Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0975367 | 122011000009 | Germany | ⤷ Start Trial | PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831 |
| 1635783 | C300653 | Netherlands | ⤷ Start Trial | PRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906 |
| 0383579 | C960030 | Netherlands | ⤷ Start Trial | PRODUCT NAME: REMIFENTANYLUM, DESGEWENST IN DE VORM VAN EEN ZUURADDITIE-ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 20601 - RVG 20603 19961015; 36335.00.00, 36335.01.00, 36335.02.00 19960517 |
| 0836511 | SPC/GB06/022 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: FENTANYL HYDROCHLORIDE; REGISTERED: UK EU/1/05/326/001 20060124 |
| 0236342 | 97C0107 | Belgium | ⤷ Start Trial | PRODUCT NAME: TIAGABINE CHLORHYDRATE MONOHYDRATE - TIAGABINE ANHYDRE; NAT. REGISTRATION NO/DATE: 403 IS 102 F 3 19970602; FIRST REGISTRATION: FR 341 260.2 19960614 |
| 1635783 | 300653 | Netherlands | ⤷ Start Trial | PRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
